MediWound Ltd. (MDWD) Receives Consensus Recommendation of “Buy” from Analysts
Shares of MediWound Ltd. (NASDAQ:MDWD) have been given a consensus rating of “Buy” by the six research firms that are currently covering the stock. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $13.25.
Several equities analysts recently issued reports on MDWD shares. Wells Fargo & Co. started coverage on MediWound in a report on Wednesday, August 17th. They issued an “outperform” rating and a $14.00 price target on the stock. Zacks Investment Research cut MediWound from a “hold” rating to a “sell” rating in a report on Wednesday, October 5th. Finally, Jefferies Group decreased their price target on MediWound from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, July 29th.
A number of institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its position in MediWound by 19.4% in the first quarter. Renaissance Technologies LLC now owns 49,800 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 8,100 shares during the last quarter. United Services Automobile Association raised its position in MediWound by 125.9% in the second quarter. United Services Automobile Association now owns 123,440 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 68,800 shares during the last quarter. Wellington Management Group LLP raised its position in MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock valued at $8,431,000 after buying an additional 100,723 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in MediWound during the second quarter valued at $13,302,000. 26.48% of the stock is currently owned by hedge funds and other institutional investors.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/mediwound-ltd-mdwd-receives-consensus-recommendation-of-buy-from-analysts.html
MediWound (NASDAQ:MDWD) remained flat at $6.90 during trading on Monday. 2,007 shares of the stock were exchanged. MediWound has a 12-month low of $5.66 and a 12-month high of $10.47. The stock’s market cap is $150.77 million. The stock’s 50 day moving average is $7.57 and its 200 day moving average is $7.76.
MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.11. The business had revenue of $3.36 million for the quarter, compared to the consensus estimate of $0.45 million. MediWound had a negative return on equity of 103.14% and a negative net margin of 2,332.07%. MediWound’s revenue for the quarter was up 115.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.19) EPS. On average, equities analysts anticipate that MediWound will post ($1.02) earnings per share for the current year.
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.